Avalo Therapeutics, Inc. Common Stock (AVTX) Stock
NASDAQ · AVTX
14.97
Fundamentals
Market cap
$829.66M
Price / Earnings ratio
-8.4x
Price / Sales ratio
14289.8x
Price / Book ratio
1.9x
Return on assets
-72.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Investors Business Daily
This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout
NeutralAVTXMay 6, 2026
Investors Business DailyNeutral
This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout
AVTX

Stocktwits
AVTX Surges Over 50% After Hours as Skin Disease Drug Shows Desired Clinical Results
NeutralAVTXMay 5, 2026
StocktwitsNeutral
AVTX Surges Over 50% After Hours as Skin Disease Drug Shows Desired Clinical Results
AVTX

Zacks Investment Research
Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know
NeutralAVTXApril 3, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know
AVTX

Zacks Investment Research
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
NeutralAVTXApril 2, 2026
Zacks Investment ResearchNeutral
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
AVTX
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy3
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
7080046728233640
Debt & Balance Sheet
Total assets
Total liabilities
2025
140M92M46M0
Revenue to Profit
2025$59000.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-78.3M
Net incomeEarnings
No data available
% positive news of 7 articles
published over the past 14 days
Latest news

Investors Business Daily
This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout
NeutralAVTXMay 6, 2026
Investors Business DailyNeutral
This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout
AVTX

Stocktwits
AVTX Surges Over 50% After Hours as Skin Disease Drug Shows Desired Clinical Results
NeutralAVTXMay 5, 2026
StocktwitsNeutral
AVTX Surges Over 50% After Hours as Skin Disease Drug Shows Desired Clinical Results
AVTX

Zacks Investment Research
Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know
NeutralAVTXApril 3, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know
AVTX

Zacks Investment Research
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
NeutralAVTXApril 2, 2026
Zacks Investment ResearchNeutral
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
AVTX

Zacks Investment Research
New Strong Buy Stocks for November 27th
NeutralAVTXNovember 27, 2023
Zacks Investment ResearchNeutral
New Strong Buy Stocks for November 27th
AVTX

PennyStocks
3 Penny Stocks To Buy For Under $1, Are They Worth The Risk?
NeutralAVTXSeptember 19, 2023
PennyStocksNeutral
3 Penny Stocks To Buy For Under $1, Are They Worth The Risk?
AVTX

InvestorPlace
The 7 Best Biotech Stocks for Personalized Medicine Investors
NeutralAVTXApril 25, 2023
InvestorPlaceNeutral
The 7 Best Biotech Stocks for Personalized Medicine Investors
AVTX
About Avalo Therapeutics, Inc. Common Stock
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
SectorHealthcare
IndustryBiotechnology
Employees33
CEODr. Garry A. Neil M.D.
IPO DateNov 13, 2015
HeadquartersWayne, PA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Garry A. Neil M.D. | President, CEO & Director | 1954 |
| Dr. Mittie Doyle FACR, M.D. | Chief Medical Officer | 1965 |
| Mr. Taylor Boyd | Chief Business Officer | 1989 |
| Dr. Solomon H. Snyder M.D. | Founder and Chairman of Scientific Advisory Board | 1939 |
| Dr. Barbara S. Slusher Ph.D. | Founder and Member of Scientific Advisory Board | 1965 |
| Mr. Christopher Ryan Sullivan CPA | CFO & Head of Investor relations | 1984 |
| Mr. Paul C. Varki J.D., M.P.H | Chief Legal Officer | 1973 |
| Ms. Ashley Ivanowicz | Senior Vice President of Human Resources | — |
| Dr. Dino C. Miano Ph.D. | Senior Vice President of CMC & Technical Operations | — |
| Ms. Jennifer Riley | Chief Strategy Officer | 1975 |
Fundamentals
Valuation
Market cap$829.66M
Price-to-sales ratio14,289.83
Price-to-book value1.88
Price-earnings ratio-8.40
Return on Equity-98.00%
Return on Sales-143341.00%
Return on Assets-72.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-4.37
Income Statement
Average volume1,078,601
EBITDA$-84.34M
1 year high (52w)$24.27
1 year low (52w)$10.70
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
3 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$38.67
Est return
149.95%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -17.0 | -19.8 | +16.3 | +17.3 | +5.6 | +7.1 | -18.4 |



